| scholarly article | Q13442814 |
| P2093 | author name string | Claudio Anasetti | |
| Joseph Pidala | |||
| Anandharaman Veerapathran | |||
| Xue-Zhong Yu | |||
| Francisca Beato | |||
| P2860 | cites work | Human T regulatory cell therapy: take a billion or so and call me in the morning | Q24656069 |
| Two subsets of memory T lymphocytes with distinct homing potentials and effector functions | Q28146072 | ||
| Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin | Q28475626 | ||
| IDO expression by dendritic cells: tolerance and tryptophan catabolism | Q29614752 | ||
| CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells | Q29618394 | ||
| Lymphocyte homing and homeostasis | Q29619924 | ||
| Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia | Q33629928 | ||
| Specificity of CD4+CD25+ regulatory T cell function in alloimmunity | Q33736744 | ||
| Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation | Q34162461 | ||
| Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta | Q34517421 | ||
| Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells. | Q34518941 | ||
| CD4(+)CD25(+) immunoregulatory T Cells: new therapeutics for graft-versus-host disease | Q34525987 | ||
| Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells | Q36228688 | ||
| CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade | Q36369151 | ||
| Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation | Q36370863 | ||
| Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells | Q36371345 | ||
| Clinical application of expanded CD4+25+ cells | Q36386636 | ||
| Antigen-specific regulatory T cells--ex vivo expansion and therapeutic potential | Q36386898 | ||
| In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes | Q36399048 | ||
| CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. | Q36399104 | ||
| Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. | Q36641930 | ||
| The influence of IL-2 family cytokines on activation and function of naturally occurring regulatory T cells | Q36882243 | ||
| CD28 costimulation is essential for human T regulatory expansion and function | Q36916914 | ||
| Expansion of human regulatory T-cells from patients with type 1 diabetes | Q37105331 | ||
| Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells | Q37180691 | ||
| Regulatory T cells after organ transplantation: where does their action take place? | Q37220729 | ||
| Cord blood CD4(+)CD25(+)-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function | Q40514795 | ||
| Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells. | Q40565739 | ||
| Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood | Q41973912 | ||
| Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood | Q41988688 | ||
| Generation and large-scale expansion of human inducible regulatory T cells that suppress graft-versus-host disease | Q42000621 | ||
| Efficient and selective prevention of GVHD by antigen-specific induced Tregs via linked-suppression in mice | Q42109680 | ||
| ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays | Q43536416 | ||
| Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic mice | Q46081630 | ||
| L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. | Q50796687 | ||
| Only the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. | Q51980108 | ||
| CD27/CFSE-based ex vivo selection of highly suppressive alloantigen-specific human regulatory T cells. | Q51991426 | ||
| IL-15 and cognate antigen successfully expand de novo-induced human antigen-specific regulatory CD4+ T cells that require antigen-specific activation for suppression. | Q52003802 | ||
| Antigen-dependent suppression of alloresponses by Foxp3-induced regulatory T cells in transplantation. | Q53663389 | ||
| Expansion of CD4+ CD25+ Foxp3+ T cells by bone marrow-derived dendritic cells | Q60321275 | ||
| IL-10 Is Required for Regulatory T Cells to Mediate Tolerance to Alloantigens In Vivo | Q60700622 | ||
| The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality | Q78033315 | ||
| Ex vivo depletion of alloreactive cells based on CFSE dye dilution, activation antigen selection, and dendritic cell stimulation | Q79116877 | ||
| Generation and expansion of human CD4+ CD25+ regulatory T cells with indirect allospecificity: Potential reagents to promote donor-specific transplantation tolerance | Q79468642 | ||
| CD4 CD25high regulatory T cells are not impaired in patients with primary Sjögren's syndrome | Q81679698 | ||
| P433 | issue | 20 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 5671-5680 | |
| P577 | publication date | 2011-09-23 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Ex vivo expansion of human Tregs specific for alloantigens presented directly or indirectly | |
| P478 | volume | 118 |
| Q40132561 | Adoptive T Regulatory Cell Therapy for Tolerance Induction |
| Q58752977 | Adoptive transfer of xenoantigen‑stimulated T cell receptor Vβ‑restricted human regulatory T cells prevents porcine islet xenograft rejection in humanized mice |
| Q39051114 | Advances in islet encapsulation technologies |
| Q85932260 | Alloreactive regulatory T cells generated with retinoic acid prevent skin allograft rejection |
| Q37603816 | Attenuation of donor-reactive T cells allows effective control of allograft rejection using regulatory T cell therapy |
| Q90549074 | Autoimmunity in Acute Myocarditis: How Immunopathogenesis Steers New Directions for Diagnosis and Treatment |
| Q35207094 | CD4+ T cell STAT3 phosphorylation precedes acute GVHD, and subsequent Th17 tissue invasion correlates with GVHD severity and therapeutic response. |
| Q35888837 | CD4+ T cells in aged or thymectomized recipients of allogeneic stem cell transplantations |
| Q39279238 | Cell Therapy in Kidney Transplantation: Focus on Regulatory T Cells |
| Q52682313 | Clinical Grade Regulatory CD4+ T Cells (Tregs): Moving Toward Cellular-Based Immunomodulatory Therapies. |
| Q34038443 | Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation. |
| Q35763504 | Donor Requirements for Regulatory T Cell Suppression of Murine Graft-versus-Host Disease |
| Q41658209 | Donor-Reactive Regulatory T Cell Frequency Increases During Acute Cellular Rejection of Lung Allografts |
| Q64982406 | Early expansion of donor-specific Tregs in tolerant kidney transplant recipients. |
| Q55433915 | Equal Expansion of Endogenous Transplant-Specific Regulatory T Cell and Recruitment Into the Allograft During Rejection and Tolerance. |
| Q56886145 | Ex Vivo Generation of Donor Antigen-Specific Immunomodulatory Cells: A Comparison Study of Anti-CD80/86 mAbs and CTLA4-lg Costimulatory Blockade |
| Q52721830 | Gene Therapy With Regulatory T Cells: A Beneficial Alliance. |
| Q48215037 | Generation and Characterization of Alloantigen-Specific Regulatory T Cells For Clinical Transplant Tolerance |
| Q46059376 | Generation of Human Alloantigen-Specific Regulatory T Cells Under Good Manufacturing Practice-Compliant Conditions for Cell Therapy |
| Q38193165 | Harnessing regulatory T cells for clinical use in transplantation: the end of the beginning |
| Q44688219 | Helicobacter pylori induces in-vivo expansion of human regulatory T cells through stimulating interleukin-1β production by dendritic cells |
| Q37202298 | Human regulatory T cells against minor histocompatibility antigens: ex vivo expansion for prevention of graft-versus-host disease |
| Q36036340 | Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. |
| Q89965796 | Interleukin-27 Enforces Regulatory T Cell Functions to Prevent Graft-versus-Host Disease |
| Q36016618 | Kv1.3 deletion biases T cells toward an immunoregulatory phenotype and renders mice resistant to autoimmune encephalomyelitis |
| Q92001013 | Large-Scale Generation of Human Allospecific Induced Tregs With Functional Stability for Use in Immunotherapy in Transplantation |
| Q41531533 | Large-scale in vitro expansion of human regulatory T cells with potent xenoantigen-specific suppression |
| Q91707988 | Mechanisms of Immune Tolerance in Liver Transplantation-Crosstalk Between Alloreactive T Cells and Liver Cells With Therapeutic Prospects |
| Q90733169 | Natural Killer Cells Promote Kidney Graft Rejection Independently of Cyclosporine A Therapy |
| Q38057376 | New ways to separate graft-versus-host disease and graft-versus-tumour effects after allogeneic haematopoietic stem cell transplantation |
| Q38614123 | Pharmacologic targeting of regulatory T cells for solid organ transplantation: current and future prospects |
| Q38235166 | Potential and limitations of regulatory T-cell therapy in solid organ transplantation. |
| Q38794663 | Recent advances and current state of immunotherapy in systemic lupus erythematosus |
| Q36462109 | Regulatory T Cell Immunotherapy in Immune-Mediated Diseases |
| Q88777827 | Regulatory T Cells and Kidney Transplantation |
| Q26784460 | Regulatory T Cells: Serious Contenders in the Promise for Immunological Tolerance in Transplantation |
| Q37272005 | Regulatory T cells and natural killer T cells for modulation of GVHD following allogeneic hematopoietic cell transplantation |
| Q38557841 | Regulatory T cells: tolerance induction in solid organ transplantation |
| Q37309438 | Regulatory T-Cell Therapy for Graft-versus-host Disease |
| Q27025869 | Regulatory T-cell therapy in transplantation: moving to the clinic |
| Q26865816 | Regulatory cells and transplantation tolerance |
| Q38889434 | Restimulation After Cryopreservation and Thawing Preserves the Phenotype and Function of Expanded Baboon Regulatory T Cells. |
| Q41137721 | Single and combined effect of retinoic acid and rapamycin modulate the generation, activity and homing potential of induced human regulatory T cells. |
| Q35623772 | Survivin-specific CD4+ T cells are decreased in patients with survivin-positive myeloma |
| Q46045077 | T cells expressing chimeric antigen receptor promote immune tolerance. |
| Q37700178 | Th17 cells and Tregs: unlikely allies |
| Q28076264 | The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease |
| Q27015124 | The place of immunotherapy in the management of HCV-induced vasculitis: an update |
| Q92916933 | The promise of CD4+FoxP3+ regulatory T-cell manipulation in vivo: applications for allogeneic hematopoietic stem cell transplantation |
| Q91559975 | The pursuit of transplantation tolerance: new mechanistic insights |
| Q38117369 | The role of regulatory T cells in the biology of graft versus host disease. |
| Q91881931 | Tolerogenic vaccine composited with islet-derived multipeptides and cyclosporin A induces pTreg and prevents Type 1 diabetes in murine model |
| Q61805676 | Transient increase of activated regulatory T cells early after kidney transplantation |
| Q39406891 | Transplant trials with Tregs: perils and promises |
| Q91768573 | Treg cell-based therapies: challenges and perspectives |
| Q28078405 | What Is Direct Allorecognition? |
| Q49830795 | c-Jun N-terminal kinase 1 defective CD4+CD25+FoxP3+ cells prolong islet allograft survival in diabetic mice |
Search more.